[1]JournalofMedicinalChemistry,2006,vol.49,p.6465-6488
[2]Patent:CN107814793,2018,A.Locationinpatent:Paragraph0018;0021
[3]Patent:CN107987064,2018,A.Locationinpatent:Paragraph0013;0014;0015
[1]Hennequin,LaurentF.;Allen,Jack;Breed,Jason;Curwen,Jon;Fennell,Michael;Green,TimP.;Lambert-VanDerBrempt,Christine;Morgentin,Rémy;Norman,RichardA.;Olivier,Annie;Otterbein,Ludovic;Plé,PatrickA.;Warin,Nicolas;Costello,Gerard[JournalofMedicinalChemistry,2006,vol.49,#22,p.6465-6488]
[1]Hennequin,LaurentF.;Allen,Jack;Breed,Jason;Curwen,Jon;Fennell,Michael;Green,TimP.;Lambert-VanDerBrempt,Christine;Morgentin,Rémy;Norman,RichardA.;Olivier,Annie;Otterbein,Ludovic;Plé,PatrickA.;Warin,Nicolas;Costello,Gerard[JournalofMedicinalChemistry,2006,vol.49,#22,p.6465-6488]
[1]Hennequin,LaurentF.;Allen,Jack;Breed,Jason;Curwen,Jon;Fennell,Michael;Green,TimP.;Lambert-VanDerBrempt,Christine;Morgentin,Rémy;Norman,RichardA.;Olivier,Annie;Otterbein,Ludovic;Plé,PatrickA.;Warin,Nicolas;Costello,Gerard[JournalofMedicinalChemistry,2006,vol.49,#22,p.6465-6488]
[1]Hennequin,LaurentF.;Allen,Jack;Breed,Jason;Curwen,Jon;Fennell,Michael;Green,TimP.;Lambert-VanDerBrempt,Christine;Morgentin,Rémy;Norman,RichardA.;Olivier,Annie;Otterbein,Ludovic;Plé,PatrickA.;Warin,Nicolas;Costello,Gerard[JournalofMedicinalChemistry,2006,vol.49,#22,p.6465-6488]
Title: Cytochrome P450 Mediated Bioactivation of Saracatinib.
Journal: Chemical research in toxicology 20161121
Title: Fragment-Based Discovery of Potent and Selective DDR1/2 Inhibitors.
Journal: ACS medicinal chemistry letters 20150709
Title: Lipopolysaccharide-induced caveolin-1 phosphorylation-dependent increase in transcellular permeability precedes the increase in paracellular permeability.
Journal: Drug design, development and therapy 20150101
Title: Identification of potent Yes1 kinase inhibitors using a library screening approach.
Journal: Bioorganic & medicinal chemistry letters 20130801
Title: Saracatinib (AZD0530) is a potent modulator of ABCB1-mediated multidrug resistance in vitro and in vivo.
Journal: International journal of cancer 20130101
Title: Phase I open-label study of cediranib, an oral inhibitor of VEGF signalling, in combination with the oral Src inhibitor saracatinib in patients with advanced solid tumours.
Journal: Investigational new drugs 20121001
Title: Src-signaling interference impairs the dissemination of blood-borne tumor cells.
Journal: Cell and tissue research 20120801
Title: Antitumor activity of Src inhibitor saracatinib (AZD-0530) in preclinical models of biliary tract carcinomas.
Journal: Molecular cancer therapeutics 20120701
Title: False-negative MRI biomarkers of tumour response to targeted cancer therapeutics.
Journal: British journal of cancer 20120605
Title: A phase II trial of the Src kinase inhibitor saracatinib (AZD0530) in patients with metastatic or locally advanced gastric or gastro esophageal junction (GEJ) adenocarcinoma: a trial of the PMH phase II consortium.
Journal: Investigational new drugs 20120601
Title: Simultaneous targeting of Src kinase and receptor tyrosine kinase results in synergistic inhibition of renal cell carcinoma proliferation and migration.
Journal: International journal of cancer 20120601
Title: Phase I study of saracatinib (AZD0530) in combination with paclitaxel and/or carboplatin in patients with solid tumours.
Journal: British journal of cancer 20120522
Title: Role of Src in breast cancer cell migration and invasion in a breast cell/bone-derived cell microenvironment.
Journal: Breast cancer research and treatment 20120501
Title: Distinct effects of saracatinib on memory CD8+ T cell differentiation.
Journal: Journal of immunology (Baltimore, Md. : 1950) 20120501
Title: Common PIK3CA mutants and a novel 3' UTR mutation are associated with increased sensitivity to saracatinib.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research 20120501
Title: A phase I/II study of the Src inhibitor saracatinib (AZD0530) in combination with gemcitabine in advanced pancreatic cancer.
Journal: Investigational new drugs 20120401
Title: Effects of Src kinase inhibition by saracatinib (AZD0530) on bone turnover in advanced malignancy in a Phase I study.
Journal: Bone 20120401
Title: An update on dual Src/Abl inhibitors.
Journal: Future medicinal chemistry 20120401
Title: TRAF6 inhibits proangiogenic signals in endothelial cells and regulates the expression of vascular endothelial growth factor.
Journal: Biochemical and biophysical research communications 20120302
Title: WZ4002, a third-generation EGFR inhibitor, can overcome anoikis resistance in EGFR-mutant lung adenocarcinomas more efficiently than Src inhibitors.
Journal: Laboratory investigation; a journal of technical methods and pathology 20120301
Title: Modulation of epithelial tight junctions by TGF-beta 3 in cultured oral epithelial cells.
Journal: Australian dental journal 20120301
Title: In silico investigation of potential SRC kinase ligands from traditional Chinese medicine.
Journal: PloS one 20120101
Title: Traditional Chinese medicine as dual guardians against hypertension and cancer?
Journal: Journal of biomolecular structure & dynamics 20120101
Title: Hepatitis B virus large surface antigen promotes liver carcinogenesis by activating the Src/PI3K/Akt pathway.
Journal: Cancer research 20111215
Title: Phase II trial of saracatinib (AZD0530), an oral SRC-inhibitor for the treatment of patients with hormone receptor-negative metastatic breast cancer.
Journal: Clinical breast cancer 20111001
Title: Expression and functional role of CRIPTO-1 in cutaneous melanoma.
Journal: British journal of cancer 20110927
Title: Simultaneous exposure of transformed cells to SRC family inhibitors and CHK1 inhibitors causes cell death.
Journal: Cancer biology & therapy 20110801
Title: Combined Src and ER blockade impairs human breast cancer proliferation in vitro and in vivo.
Journal: Breast cancer research and treatment 20110701
Title: Current status of SRC inhibitors in solid tumor malignancies.
Journal: The oncologist 20110501
Title: Synthesis and pharmacological evaluation of thieno[2,3-b]pyridine derivatives as novel c-Src inhibitors.
Journal: Bioorganic & medicinal chemistry 20110415
Title: Osteoporosis: now and the future.
Journal: Lancet (London, England) 20110409
Title: Phase II study of saracatinib (AZD0530) for patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC).
Journal: Anticancer research 20110101
Title: Impact of the Src inhibitor saracatinib on the metastatic phenotype of a fibrosarcoma (KHT) tumor model.
Journal: Anticancer research 20101101
Title: Phase I safety, pharmacokinetics, and inhibition of SRC activity study of saracatinib in patients with solid tumors.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research 20101001
Title: [SRC kinases in tumor therapy].
Journal: Medizinische Klinik (Munich, Germany : 1983) 20101001
Title: Gene array and fluorescence in situ hybridization biomarkers of activity of saracatinib (AZD0530), a Src inhibitor, in a preclinical model of colorectal cancer.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research 20100815
Title: Novel dual Src/Abl inhibitors for hematologic and solid malignancies.
Journal: Expert opinion on investigational drugs 20100801
Title: Src family kinase inhibitor Saracatinib (AZD0530) impairs oxaliplatin uptake in colorectal cancer cells and blocks organic cation transporters.
Journal: Cancer research 20100715
Title: Effects of the Src inhibitor saracatinib (AZD0530) on renal function in healthy subjects.
Journal: Anticancer research 20100701
Title: Emerging targets in osteoporosis disease modification.
Journal: Journal of medicinal chemistry 20100610
Title: A novel bile acid-activated vitamin D receptor signaling in human hepatocytes.
Journal: Molecular endocrinology (Baltimore, Md.) 20100601
Title: Effect of the specific Src family kinase inhibitor saracatinib on osteolytic lesions using the PC-3 bone model.
Journal: Molecular cancer therapeutics 20100601
Title: Effects of the Src kinase inhibitor saracatinib (AZD0530) on bone turnover in healthy men: a randomized, double-blind, placebo-controlled, multiple-ascending-dose phase I trial.
Journal: Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 20100301
Title: Src tyrosine kinase regulates adhesion and chemotaxis in Waldenstrom macroglobulinemia.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research 20091001
Title: Antitumor effects and biomarkers of activity of AZD0530, a Src inhibitor, in pancreatic cancer.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research 20090615
Title: Inhibition of Src with AZD0530 reveals the Src-Focal Adhesion kinase complex as a novel therapeutic target in papillary and anaplastic thyroid cancer.
Journal: The Journal of clinical endocrinology and metabolism 20090601
Title: Preclinical anticancer activity of the potent, oral Src inhibitor AZD0530.
Journal: Molecular oncology 20090601
Title: Combined Src and aromatase inhibition impairs human breast cancer growth in vivo and bypass pathways are activated in AZD0530-resistant tumors.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research 20090515
Title: Dual targeting of Src and ER prevents acquired antihormone resistance in breast cancer cells.
Journal: Breast cancer research and treatment 20090501
Title: Structure-based virtual screening of Src kinase inhibitors.
Journal: Bioorganic & medicinal chemistry 20090415
Title: The Src inhibitor AZD0530 blocks invasion and may act as a radiosensitizer in lung cancer cells.
Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20090401
Title: The Src inhibitor AZD0530 reversibly inhibits the formation and activity of human osteoclasts.
Journal: Molecular cancer research : MCR 20090401
Title: Src inhibitors in early breast cancer: a methodology, feasibility and variability study.
Journal: Breast cancer research and treatment 20090301
Title: Quantification of focal adhesion kinase activation loop phosphorylation as a biomarker of Src activity.
Journal: Molecular pharmacology 20090301
Title: A phase II trial of the Src-kinase inhibitor AZD0530 in patients with advanced castration-resistant prostate cancer: a California Cancer Consortium study.
Journal: Anti-cancer drugs 20090301
Title: A novel Src kinase inhibitor reduces tumour formation in a skin carcinogenesis model.
Journal: Carcinogenesis 20090201
Title: Src as a therapeutic target in men with prostate cancer and bone metastases.
Journal: BJU international 20090201
Title: Improved response by co-targeting EGFR/EGFRvIII and Src family kinases in human cancer cells.
Journal: Cancer investigation 20090201
Title: Activation of Src and Src-associated signaling pathways in relation to hypoxia in human cancer xenograft models.
Journal: International journal of cancer 20090115
Title: Aberrant activation of androgen receptor in a new neuropeptide-autocrine model of androgen-insensitive prostate cancer.
Journal: Cancer research 20090101
Title: The effect of the dual Src/Abl kinase inhibitor AZD0530 on Philadelphia positive leukaemia cell lines.
Journal: BMC cancer 20090101
Title: Src family kinase oncogenic potential and pathways in prostate cancer as revealed by AZD0530.
Journal: Oncogene 20081023
Title: Research provides new hope for tamoxifen-resistant breast cancer patients.
Journal: Women's health (London, England) 20080301
Title: Structure-guided development of affinity probes for tyrosine kinases using chemical genetics.
Journal: Nature chemical biology 20070401
Title: Cooperative action of tamoxifen and c-Src inhibition in preventing the growth of estrogen receptor-positive human breast cancer cells.
Journal: Molecular cancer therapeutics 20061201
Title: N-(5-chloro-1,3-benzodioxol-4-yl)-7-[2-(4-methylpiperazin-1-yl)ethoxy]-5- (tetrahydro-2H-pyran-4-yloxy)quinazolin-4-amine, a novel, highly selective, orally available, dual-specific c-Src/Abl kinase inhibitor.
Journal: Journal of medicinal chemistry 20061102
Title: Clinical development of SRC tyrosine kinase inhibitors in lung cancer.
Journal: Clinical lung cancer 20060501
Title: Green TP, et al. Preclinical anticancer activity of the potent, oral Src inhibitor AZD0530. Mol Oncol, 2009, 3(3), 248-261.
Title: Fuse MA, et al. Combination Therapy With c-Met and Src Inhibitors Induces Caspase-Dependent Apoptosis of Merlin-Deficient Schwann Cells and Suppresses Growth of Schwannoma Cells. Mol Cancer Ther. Mol Cancer Ther. 2017 Nov;16(11):2387-2398.
